Table 6.
Multivariable hazard ratios (HR) and 95 % confidence intervals (CIs) for risk of endometrial cancer by tertiles of metabolic ratios
| Estrogen/EM | Cases (n = 66) | Subcohort (n = 346) | HR (95 % CI)a | HR (95 % CI)b | HR (95 % CI)c |
|---|---|---|---|---|---|
| Metabolic ratios | |||||
| 2-Pathway/parents | |||||
| T1 | 22 | 115 | 1.00 | 1.00 | |
| T2 | 24 | 113 | 1.22 (0.63, 2.36) | 1.23 (0.62, 2.46) | n/a |
| T3 | 20 | 118 | 0.88 (0.45, 1.73) | 1.07 (0.53, 2.15) | n/a |
| p trend | 0.71 | 0.89 | n/a | ||
| 4-Pathway/parents | |||||
| T1 | 29 | 114 | 1.00 | 1.00 | |
| T2 | 16 | 115 | 0.52 (0.26, 1.06) | 0.49 (0.24, 1.01) | n/a |
| T3 | 21 | 117 | 0.69 (0.37, 1.32) | 0.82 (0.41, 1.61) | n/a |
| p trend | 0.26 | 0.48 | n/a | ||
| 16-Pathway/parents | |||||
| T1 | 31 | 115 | 1.00 | 1.00 | |
| T2 | 18 | 113 | 0.66 (0.34, 1.30) | 0.73 (0.37, 1.43) | n/a |
| T3 | 17 | 118 | 0.63 (0.33, 1.21) | 0.72 (0.35, 1.50) | n/a |
| p trend | 0.15 | 0.32 | n/a | ||
| 2-Pathway/16-pathway | |||||
| T1 | 17 | 115 | 1.00 | 1.00 | 1.00 |
| T2 | 22 | 114 | 1.19 (0.57, 2.49) | 1.48 (0.68, 3.22) | 1.29 (0.61, 2.73) |
| T3 | 27 | 117 | 1.23 (0.60, 2.53) | 1.49 (0.71, 3.12) | 1.78 (0.88, 3.61) |
| p trend | 0.58 | 0.32 | 0.11 | ||
| 4-Pathway/2-pathway | |||||
| T1 | 29 | 115 | 1.00 | 1.00 | 1.00 |
| T2 | 15 | 113 | 0.52 (0.26, 1.06) | 0.58 (0.28, 1.16) | 0.61 (0.29, 1.28) |
| T3 | 22 | 118 | 0.91 (0.48, 1.74) | 0.97 (0.50, 1.88) | 1.22 (0.61, 2.44) |
| p trend | 0.68 | 0.85 | 0.71 | ||
| 4-Pathway/16-pathway | |||||
| T1 | 22 | 114 | 1.00 | 1.00 | 1.00 |
| T2 | 23 | 115 | 0.93 (0.47, 1.84) | 1.13 (0.56, 2.25) | 1.16 (0.57, 2.35) |
| T3 | 21 | 117 | 0.87 (0.44, 1.73) | 1.05 (0.52, 2.13) | 1.46 (0.70, 3.05) |
| p trend | 0.70 | 0.90 | 0.32 | ||
| 2-OHE/16α-OHE | |||||
| T1 | 19 | 115 | 1.00 | 1.00 | 1.00 |
| T2 | 17 | 114 | 1.09 (0.53, 2.23) | 1.31 (0.61, 2.79) | 1.08 (0.50, 2.32) |
| T3 | 30 | 117 | 1.63 (0.86, 3.07) | 1.83 (0.93, 3.58) | 2.09 (1.09, 4.01) |
| p trend | 0.13 | 0.11 | 0.03 | ||
| 2-Catechol/2-methylated | |||||
| T1 | 6 | 115 | 1.00 | 1.00 | 1.00 |
| T2 | 22 | 113 | 3.03 (1.17, 7.88) | 2.81 (1.05, 7.51) | 2.88 (1.10, 7.53) |
| T3 | 38 | 118 | 4.49 (1.81, 11.18) | 4.08 (1.58, 10.44) | 4.02 (1.60, 10.13) |
| p trend | 0.0006 | 0.002 | 0.002 | ||
| 4-Catechol/4-methylated | |||||
| T1 | 5 | 114 | 1.00 | 1.00 | 1.00 |
| T2 | 18 | 114 | 2.83 (0.99, 8.09) | 2.64 (0.91, 7.66) | 2.50 (0.87, 7.19) |
| T3 | 43 | 118 | 5.67 (2.06, 15.60) | 5.39 (1.95, 14.94) | 4.59 (1.64, 12.88) |
| p trend | 0.0002 | 0.0003 | 0.002 | ||
| 2-Catechol/parents | |||||
| T1 | 16 | 115 | 1.00 | 1.00 | |
| T2 | 29 | 113 | 1.74 (0.87, 3.50) | 1.68 (0.84, 3.36) | n/a |
| T3 | 21 | 118 | 1.16 (0.55, 2.44) | 1.35 (0.65, 2.80) | n/a |
| p trend | 0.75 | 0.47 | n/a | ||
| 2-Methylated/parents | |||||
| T1 | 30 | 115 | 1.00 | 1.00 | |
| T2 | 23 | 114 | 0.93 (0.50, 1.72) | 0.95 (0.49, 1.85) | n/a |
| T3 | 13 | 117 | 0.49 (0.24, 0.99) | 0.56 (0.26, 1.19) | n/a |
| p trend | 0.05 | 0.14 | n/a | ||
| 4-Catechol/parents | |||||
| T1 | 12 | 115 | 1.00 | 1.00 | |
| T2 | 32 | 114 | 2.19 (1.03, 4.64) | 2.28 (1.06, 2.92) | n/a |
| T3 | 22 | 117 | 1.58 (0.71, 3.50) | 1.87 (0.83, 4.23) | n/a |
| p trend | 0.34 | 0.16 | n/a | ||
| 4-Methylated/parents | |||||
| T1 | 35 | 115 | 1.00 | 1.00 | |
| T2 | 15 | 113 | 0.53 (0.27, 1.05) | 0.52 (0.25, 1.06) | n/a |
| T3 | 16 | 118 | 0.59 (0.31, 1.15) | 0.67 (0.34, 1.34) | n/a |
| p trend | 0.10 | 0.19 | n/a | ||
The following tertile categories (T1, T2, T3 pmol/L) determined based on the distribution of each estrogen or estrogen metabolite among the subcohort: 2-pathway/parents (<0.328, 0.328-0.434, >0.434), 4-pathway/parents (0.045, 0.045–0.061, >0.061), 16-pathway/parents (0.896, 0.896–1.06, >1.06), 2-pathway/16-pathway (<0.355, 0.355–0.422, >0.423), 4-pathway/2-pathway (<0.135, 0.135–0.149, >0.149), 4-pathway/16-pathway (<0.50, 0.50–0.06, >0.06), 2-OHE/16-OHE (<2.06, 2.06–2.27, >2.27), 2-catechol/2-methylated (<1.50, 1.50–1.99, >1.99), 4-catechol/4-methylated (<1.30, 1.30–1.96, >1.96), 2-catechol/parents (<0.194, 0.194–0.279, >0.279), 2-methylated/parents (<0.118, 0.118–0.162, >0.162), 4-catechols/parents (<0.0248, 0.0248–0.0396, >0.0396), 4-methylated/parents (<0.0169, 0.0169–0.0254, >0.254)
aAdjusted for clinic and trial participation status
bAdjusted for clinic, trial participation status, and body mass index
cAdjusted for clinic, trial participation status, and estradiol